射血分数未降低心肌梗死后的β受体阻滞剂治疗
该开放标签随机试验在西班牙和意大利纳入急性心肌梗死(伴或不伴ST段抬高)且左室射血分数>40%的患者,比较β受体阻滞剂治疗与不使用β受体阻滞剂。共4243例分配至β受体阻滞剂组、4262例分配至无β受体阻滞剂组,排除后8438例纳入主要分析。中位随访3.7年,主要复合终点(全因死亡、再梗死或心衰住院)在β受体阻滞剂组316例(22.5事件/1000患者年) vs 无β受体阻滞剂组307例(21.7事件/1000患者年),HR 1.04(95%CI 0.89–1.22;P=0.63)。全因死亡、再梗死、心衰住院及安全性结局组间均无显著差异。
要点
- 射血分数>40%的心梗患者侵入性治疗后出院,β受体阻滞剂组主要复合终点22.5事件/1000患者年 vs 无β受体阻滞剂组21.7事件/1000患者年,HR 1.04(95%CI 0.89–1.22;P=0.63)。
- 全因死亡:β受体阻滞剂组161例(11.2事件/1000患者年) vs 无β受体阻滞剂组153例(10.5事件/1000患者年),HR 1.06(95%CI 0.85–1.33)。
- 再梗死:两组各143例(10.2 vs 10.1事件/1000患者年),HR 1.01(95%CI 0.80–1.27)。
- 心衰住院:β受体阻滞剂组39例(2.7事件/1000患者年) vs 无β受体阻滞剂组44例(3.0事件/1000患者年),HR 0.89(95%CI 0.58–1.38)。
- 安全性结局未见明显组间差异。
适用人群与场景
- 急性心肌梗死(伴或不伴ST段抬高)且左室射血分数>40%、接受侵入性治疗后出院的患者。
- 研究在西班牙和意大利开展。
诊断标准与关键阈值
- 左室射血分数>40%。
研究设计与关键结果
- 开放标签随机试验,纳入急性心肌梗死(伴或不伴ST段抬高)且左室射血分数>40%的患者,比较β受体阻滞剂治疗与不使用β受体阻滞剂。
- 共4243例随机分配至β受体阻滞剂组、4262例分配至无β受体阻滞剂组;排除后8438例纳入主要分析。
- 中位随访3.7年,主要复合终点(全因死亡、再梗死或心衰住院)在β受体阻滞剂组316例(22.5事件/1000患者年) vs 无β受体阻滞剂组307例(21.7事件/1000患者年),HR 1.04(95%CI 0.89–1.22;P=0.63)。
- 全因死亡:β受体阻滞剂组161例 vs 无β受体阻滞剂组153例(11.2 vs 10.5事件/1000患者年;HR 1.06;95%CI 0.85–1.33)。
- 再梗死:两组各143例(10.2 vs 10.1事件/1000患者年;HR 1.01;95%CI 0.80–1.27)。
- 心衰住院:β受体阻滞剂组39例 vs 无β受体阻滞剂组44例(2.7 vs 3.0事件/1000患者年;HR 0.89;95%CI 0.58–1.38)。
- 安全性结局未见明显组间差异。
证据类型、等级与局限
- 研究类型:开放标签随机试验。
- 资助:Centro Nacional de Investigaciones Cardiovasculares Carlos III等。
- 注册号:ClinicalTrials.gov NCT03596385;EudraCT 2017-002485-40。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在因心肌梗死接受侵入性治疗且左室射血分数>40%后出院的患者中,β受体阻滞剂治疗对全因死亡、再梗死或心衰住院的发生率似乎没有影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, complete revascularization, and contemporary pharmacologic therapies became standard practice.
METHODS: We conducted an open-label, randomized trial in Spain and Italy to evaluate the effect of beta-blocker therapy, as compared with no beta-blocker therapy, in patients with acute myocardial infarction (with or without ST-segment elevation) and a left ventricular ejection fraction above 40%. The primary outcome was a composite of death from any cause, reinfarction, or hospitalization for heart failure.
RESULTS: In total, 4243 patients were randomly assigned to receive beta-blocker therapy and 4262 to receive no beta-blocker therapy; after exclusions, 8438 patients were included in the main analysis. During a median follow-up of 3.7 years, a primary-outcome event occurred in 316 patients (22.5 events per 1000 patient-years) in the beta-blocker group and in 307 patients (21.7 events per 1000 patient-years) in the no-beta-blocker group (hazard ratio, 1.04; 95% confidence interval [CI], 0.89 to 1.22; P = 0.63). Death from any cause occurred in 161 patients and 153 patients, respectively (11.2 vs. 10.5 events per 1000 patient-years; hazard ratio, 1.06; 95% CI, 0.85 to 1.33); reinfarction in 143 patients and 143 patients (10.2 vs. 10.1 events per 1000 patient-years; hazard ratio, 1.01; 95% CI, 0.80 to 1.27); and hospitalization for heart failure in 39 patients and 44 patients (2.7 vs. 3.0 events per 1000 patient-years; hazard ratio, 0.89; 95% CI, 0.58 to 1.38). No apparent between-group differences in safety outcomes were noted.
CONCLUSIONS: Among patients discharged after invasive care for a myocardial infarction with a left ventricular ejection fraction above 40%, beta-blocker therapy appeared to have no effect on the incidence of death from any cause, reinfarction, or hospitalization for heart failure. (Funded by Centro Nacional de Investigaciones Cardiovasculares Carlos III and others; ClinicalTrials.gov number, NCT03596385; EudraCT number, 2017-002485-40.).
参考来源
- Ibanez B, Latini R, Rossello X, et al. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. N Engl J Med. 2025. PMID: 40888702. doi:10.1056/NEJMoa2504735
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。